Biosimilars: An Overview for Clinicians

In this educational activity experts in oncology and immunology answer your most frequently asked questions about biosimilars including:
-How biosimilars differ from their reference biologic and small molecule generics
-Safety efficacy and regulatory approval pathways
-Potential role in oncology and immunology

Share

Program Content

Activities

Downloadable Slideset
Expert Answers to Frequently Asked Questions About Biosimilars
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 09, 2017

Expires: March 08, 2018

Activities

Uncertainties With Biosimilars
Biosimilars: Addressing Uncertainties With a New Drug Class
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 13, 2017

Expires: March 12, 2018

Biosimilars in IBD
Key Considerations for Using Biosimilars in IBD
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2017

Expires: June 05, 2018

Faculty

cover img faculity

David T. Rubin, MD

Professor of Medicine
Chief,
 Section of Gastroenterology, Hepatology & Nutrition
University of Chicago Medicine
Chicago, Illinois

cover img faculity

Kenneth G. Saag, MD, MSc

Jane Knight Lowe Professor
Division of Clinical Immunology and Rheumatology
Vice Chair, Department of Medicine
Director
Center for Education and Research on Therapeutics
Center for Outcomes, Effectiveness Research and Education
Center of Research Translation in Gout and Hyperuricemia
University of Alabama at Birmingham
Birmingham, Alabama

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.